Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol)
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol) 物理性質
- 融点 :
- 62-65°C
- 沸点 :
- 598.4±50.0 °C(Predicted)
- 比重(密度) :
- 1?+-.0.06 g/cm3(Predicted)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- クロロホルム（微量）、メタノール（微量）
- 酸解離定数(Pka):
- 9.99±0.31(Predicted)
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
安全性情報
| WGK Germany |
3 |
|
|
| HSコード |
2922504500 |
|
|
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol) 価格
もっと(3)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCH948170 |
4-Hydroxy-α1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (Salmeterol Impurity) |
108928-81-0 |
2.5mg |
￥70800 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCH948170 |
4-Hydroxy-α1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (Salmeterol Impurity) |
108928-81-0 |
25mg |
￥532800 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
1609625 |
United States Pharmacopeia (USP) Reference Standard
Salmeterol Related Compound B United States Pharmacopeia (USP) Reference Standard |
108928-81-0 |
3x1.5mg |
￥201000 |
2024-03-01 |
購入 |
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol) 化学特性,用途語,生産方法
使用
4-Hydroxy-α1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol is an impurity of Salmeterol (S090100), a β2-Adrenergic agonist. Structural analog of Albuterol (A514500).
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol) 上流と下流の製品情報
原材料
準備製品
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol) 生産企業
Global( 65)Suppliers
108928-81-0()キーワード:
- 108928-81-0
- Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol)
- (4-{1-Hydroxy-2-
[6-(4-phenylbutan-2-yloxy)hexylaMino]ethyl}-2-
(hydroxyMethyl)phenol)
- 4-Hydroxy-α1-[[[6-(1-Methyl-3-phenylpropoxy)hexyl]aMino]Methyl]-1,3-benzenediMethanol
- 4-Hydroxy-α1-[[[6-(1-Methyl-3-phenylpropoxy)hexyl]aMino]Methyl]-1,3-benzenediMethanol (SalMeterol IMpurity)
- SalMeterol Related CoMpound B
- 4-Hydroxy-alpha1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
- Salmeterol Xinafoate BP Impurity E
- Salmeterol EP Impurity E
- Salmeterol Impurity 6（Salmeterol EP Impurity E ）
- 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl]phenol
- 1-[4-Hydroxy-3-(hydroxymethyl)phenyl]-2-[[6-(1-methyl-3-phenylpropoxy) hexyl] amino]ethanol
- 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-
- Salmeterol Impurity 6（EP Impurity E ）
- Salmeterol?EP Impurity E/ Salmeterol Related Compound B
- Salmeterol Related Compound B (3 x 1.3 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethy (1609625)
- Salmeterol EP Impurity E (Salmeterol USP Related Compound B)
- 4-Hydroxy-α1-[[[6-(1-methyl-3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (Salmeterol Impurity)